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Understanding how the CNS functions poses one of the greatest challenges in modern
life science and medicine. Studying the brain is especially challenging because of its
complexity, the heterogeneity of its cellular composition, and the substantial changes it
undergoes throughout its life-span. The complexity of adult brain neural networks results
also from the diversity of properties and functions of neuronal cells, governed, inter
alia, by temporally and spatially differential expression of proteins in mammalian brain
cell populations. Hence, research into the biology of CNS activity and its implications
to human and animal behavior must use novel scientific tools. One source of such
tools is the field of molecular genetics—recently utilized more and more frequently in
neuroscience research. Transgenic approaches in general, and gene targeting in rodents
have become fundamental tools for elucidating gene function in the CNS. Although
spectacular progress has been achieved over recent decades by using these approaches,
it is important to note that they face a number of restrictions. One of the main challenges
is presented by the temporal and spatial regulation of introduced genetic manipulations.
Viral vectors provide an alternative approach to temporally regulated, localized delivery of
genetic modifications into neurons. In this review we describe available technologies for
gene transfer into the adult mammalian CNS that use both viral and non-viral tools. We
discuss viral vectors frequently used in neuroscience, with emphasis on lentiviral vector
(LV) systems. We consider adverse effects of LVs, and the use of LVs for temporally
and spatially controllable manipulations. Especially, we highlight the significance of viral
vector-mediated genetic manipulations in studying learning and memory processes, and
how they may be effectively used to separate out the various phases of learning:
acquisition, consolidation, retrieval, and maintenance.
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INTRODUCTION
Our understanding of the molecular mechanisms underlying
cellular functions represents one of the major revolutions of
our era. The associated advances in genetics, molecular biology,
and biochemistry enable both conceptual breakthroughs and the
development of new technologies to study various cell types,
including neurons, in culture and in vivo. However, the nature
of mature post-mitotic neurons, and the complexity, vulnerabil-
ity, and inaccessibility of the brain impose additional constraints
on gene manipulation and molecular analysis of brain func-
tion, both in health and in sickness. These constraints include
the difficulty of exposing and manipulating the brain, the spe-
cific difficulty of introducing DNA or RNA into neurons without
harming the cells, the challenging task of manipulating a spe-
cific neuronal population among the thousands of neuronal types
present, and the limitations of genetic approaches to manipula-
tion of gene expression while maintaining the desired temporal
and spatial resolution.
A major way to overcome some of these limitations and com-
plexities is to use the natural ability of viruses to introduce genes
into host-cells, including neurons, and during the last decade
viral vector technology has been developed as a safe and rea-
sonably easy tool to use. Several features of viral vectors are
specifically attractive with regard to manipulation of the mature
brain: (a) the ability to manipulate gene expression, and pro-
tein level and activity in specific cells, e.g., in neurons rather
than in glia, by directing the viral transduction to the desired
cell type; (b) the capability to identify the manipulated cells by
co-expressing reporter genes, e.g., Enhanced Green Fluorescent
Protein (EGFP), together with the gene of interest, a capability
that is especially useful for phenotypic examination of the mor-
phological and electrophysiological properties of the transduced
cells; (c) co-expression of optogenetic tools, e.g., halorhodopsin,
in manipulating neuronal activity; (d) cell-specific expression of
viral DNA vectors, by using specific promoters; and (e) localiza-
tion of the genetic manipulation induced by local injection of
viral vectors into a specific brain region.
In this review we discuss the advantages and disadvantages
of using viral vectors to enhance or to reduce expression of
specific genes in the mature CNS, from the perspectives of
research into neuroscience in general, and into the molecu-
lar and cellular mechanisms underlying learning and memory
processes, in particular. We first discuss the methodology of
gene transfer by using viral vectors, with specific attention to
the differences between adult and non-adult tissues. We briefly
describe the viral vectors most frequently used in neuroscience
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research: herpes simplex virus type-1 (HSV-1), adeno virus (Ad),
adeno-associated virus (AAV), and lentivirus (LV), with empha-
sis on LV. We then briefly review several studies that aimed
to elucidate molecular and cellular mechanisms of the vari-
ous phases of learning and memory by using viral vectors.
This review does not address the great potential of viral vec-
tors in gene therapy of neurodegenerative or psychiatric diseases;
these topics have been reviewed elsewhere (Verma and Weitzman,
2005; Lundberg et al., 2008; Nanou and Azzouz, 2009; Dreyer,
2011).
GENE TRANSFER TECHNOLOGIES
The mammalian brain undergoes significant changes in struc-
tural architecture and functional organization in the course of its
life-span. Even though the brain has already grown to about 90%
of its adult total size by late childhood, it continues to undergo
dynamic modifications throughout adolescence and into young
adulthood. Developmental changes include proliferation and
migration of cells, which occur mostly during fetal development,
regional changes in synaptic density that take place during post-
natal development (Huttenlocher, 1979, 1990; Bourgeois et al.,
1994), and prolonged development of myelination in adult-
hood. Therefore, brain maturation may be considered as progress
toward ever-growing complexity. One aspect of this complexity
is exhibited in the brain’s thousands of intercalated but distinct
neuronal populations, which are interlinked by huge numbers of
synaptic connections.
To gain a better understanding of brain function at the cel-
lular and molecular levels, a technology is needed that facili-
tates manipulation of gene expression in vivo. Within the brain,
region-restricted and neuronal-subpopulation-restricted genetic
manipulations serve as a powerful means for elucidation of
gene function in the adult animal. Furthermore, one would
like to be able to monitor neurobiological functions, in order
to replace, modify, induce, or block expression of target genes
in a temporally and spatially controlled manner. Over the past
decade, application of gene manipulation technologies has gained
momentum in neuroscience research in the adult brain. The
ideal vector for gene delivery should efficiently package and pro-
tect the transgene, target specific neuronal subpopulations in the
body, and express the transgene within a desired time window.
In furthering this aim, research efforts have focused on evalu-
ating existing vectors and developing novel vectors for efficient
neuronal gene modifications.
At present, gene transfer technologies include viral and non-
viral approaches, and non-viral nucleic acid carriers have been
evaluated extensively, for neuronal gene delivery. These carriers
include cationic polymers, lipids, engineered polypeptides, gene
carriers based on synthetic nanoparticles, and, more recently,
in vivo electroporation-based techniques (Pere et al., 2008). The
majority of studies that use non-viral in vivo gene manipu-
lation in the brain employ these techniques for manipulating
the injured or the immature (neonatal and postnatal) brain
(Petros et al., 2009; De Vry et al., 2010; Molotkov et al., 2010;
Wong et al., 2010).
Viral vectors form another efficient tool for genetic manip-
ulation in the adult mammalian brain. Viruses have evolved
to infect host-cells and to regulate their genome expression, in
order to replicate within these cells, so that the generic virus
life cycle comprises two phases: infection and replication. The
infection step involves attachment of virions to target cells, and
subsequent introduction of the viral genome into the cell. The
replication step involves expression of the viral structural and reg-
ulatory proteins; this step is essential for viral genome replication
and for assembly of viral particles, a process termed packaging.
Viral vector technology exploits the natural features of viruses
to develop, through genetic engineering, a highly efficient tool
for gene transfer: the genes mediating viral pathogenesis and
replication are deleted and replaced with an expression cas-
sette of exogenous transgenes. The outcome of such changes
is a recombinant viral vector that effectively infects target cells
and, introduces desired transgenes into the host-cell, but is
incompetent with respect to replication. To achieve such a use-
ful vector several technological obstacles need to be overcome:
production of recombinant viral vectors requires replication-
associated genes for packaging, but these genes will have been
deleted from the viral vector itself. To overcome this issue,
replication-associated genes are supplied to the producer cell
line as trans-acting elements, so that the resulting recombinant
viral vectors can be considered relatively safe with regard to
transduction capabilities, because cell transduction can occur
only once.
An additional issue to consider in viral vector technology is
tropism. Natural viruses are most efficient at infecting specific
host-cell populations; attachment to and infection of a suscep-
tible cell are mediated by proteins expressed in the viral capsid or
envelope, and in several viral species cell recognition and speci-
ficity can be modified by replacing viral capsid/envelope proteins.
This process, termed pseudotyping, either restricts or extends the
range of cells susceptible to transduction.
VIRAL VECTORS FREQUENTLY USED IN NEUROSCIENCE
Several viral vectors derived from Ad, HSV-1, AAV, and human
immunodeficiency virus type 1 (HIV-1) were found able to
serve as powerful tools for adult brain transduction. Notably,
each of these distinct vector types has its own individual fea-
tures that should be considered before use; they include cloning
capacity, target-cell specificity, targeted-cell viability, transgene
expression duration, possible immune responses, controlled vec-
tor production, and biosafety (summarized in Table 1 and in
Papale et al., 2009).
ADENO-VIRAL VECTORS (Ad)
Ad is a non-enveloped virus that consists of a protein capsid sur-
rounding a DNA/protein core. The capsid is composed of three
major proteins—hexon (II), penton base (III), and a knobbed
fibre (IV)—along with several minor proteins (Stewart et al.,
1993). The viral genome is a linear double-stranded DNAwith an
average size of 36 kb. The Ad genome is segmented into 100map
units (mu) flanked by 100–150 bp repetitive DNA sequence
elements termed inverted terminal repeats (ITRs). In addition,
the 5′ terminus of the viral genome contains a ∼190 bp pack-
aging sequence (Russell, 2000). Both of the ITRs and the pack-
aging sequence are cis-acting elements, essential for viral DNA
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Table 1 | Features of various vector systems.
Feature Adenoviral vector HSV-1 vector AAV vector LV vector
Particle size (nm) 70–100 70–100 20–25 100
Genetic material dsDNA dsDNA ssDNA ssRNA (positive strand)
Cloning capacity (Kb) 8–10
∼30 in HD systems
150 ∼4.9 9
Chromosomal integration No No Yes (in about 10% of
infected cells)
Yes
Vector production yield High (Risk of contamination
in HD systems)
High (Risk of contamination
in HD systems)
High High
Expression onset (in vivo) 1 week 1–2 days 1–2 weeks 1–2 weeks
Expression duration (in vivo) More than six months More than two weeks More than six months More than six months
Pseudotyping? Yes Yes Yes Yes
Emergence of replicating
vectors (in vivo)?
Low risk Possible Possible but not a
concern
Risk is a concern
Insertional mutagenesis? No No ? Yes
Immune response induction Minor—in HD system Moderate (amplicon) Pre-existing neutralizing
antibodies
No
HD, Helper-dependent.
replication and packaging. The Ad genome can be divided into
early (E) and late (L) transcriptional units, according to the
time of onset of their expression during the viral life cycle. Among
the early genes, E1a and E1b proteins encode trans-activating
factors that help regulate the host-cell cycle. Furthermore, E2
is required for viral replication, E3 for host-immune mod-
ulation, and E4 to inhibit host-cell programmed cell death
(Dharmapuri et al., 2009).
To date, more than 100 Ad serotypes, including 51 human
Ad (hAd) serotypes, have been identified, and the hAd serotypes
have been classified into six distinct subgroups (A–F), according
to their characteristics such as genome size, organization, and
nucleotide composition. The best-characterized serotype is group
C, which consists of Ad serotypes 1, 2, 5, and 6, among which
serotypes 2 and 5 (Ad2 and Ad5) are the most frequently used
as gene transfer vectors (Dharmapuri et al., 2009). Ad-derived
transfer vectors harbor broad tropism properties, can transduce
both dividing and non-dividing cells without genome integration,
and can be produced at very high titers.
In first-generation Ad systems, the E1 region was deleted by
Xiang et al. (1996), which resulted in replication-incompetent
viral vectors; however, first-generation vectors induced innate
as well as adaptive immune responses (Hartman et al., 2008).
In order to reduce this toxicity, second-generation vectors were
further modified by deletion of the E2A, E3, and E4 genes,
and these improved vectors resulted in transient transgene
expression, because of induction of adaptive immune responses
(Amalfitano and Chamberlain, 1997; Amalfitano et al., 1998).
Third-generation, helper-dependent (HD) Ad vectors were pro-
duced by additional modifications; these vectors were able to
facilitate high transgene expression levels with minor toxic-
ity. In HD Ad vectors the gene transfer system consists of
transgenic DNA of length up to 36 kb that can be delivered.
However, there are production problems, such as obtaining high
titers in large-scale production, and helper-virus contamination
(Mitani et al., 1995; Kochanek et al., 1996) however, intensive
research is being conducted in order to develop an Ad-helper-cell
line that will overcome these difficulties.
HERPES SIMPLEX VIRUS TYPE-1 VIRAL VECTOR (HSV-1)
HSV-1 is an important viral vector with natural neuron-
infectivity properties. This neurotropic virus is enveloped with
a double-stranded DNA genome of about 150 kb. HSV-1 is a
non-integrating virus; in neurons, it forms a latent infection,
characterized by lack of detectable viral protein production but
continued transcriptional activity (Berges et al., 2007). Moreover,
HSV-1 is able to spread in the nervous system through retrograde
axonal transport (Cook and Stevens, 1973).
Brain infection with wild-type HSV-1 may result in encephali-
tis, therefore, a fundamental requirement for gene-transfer vec-
tors derived from this virus is reduced pathogenicity. To achieve
this, replication-deficient HSV-1-based vectors were generated
by deleting the relevant genes. Furthermore, an advanced vec-
tor system, termed an amplicon was generated by deletion of all
portions of the viral genome, except for the origin of replication
and DNA packaging sequences, leaving about 150 kb available
for transgene insertion. Production of amplicon HSV-1-based
viral particles in packaging cells involves utilization of either a
helper-virus or use of several plasmids that provide the nec-
essary trans-acting elements (Epstein, 2005; Epstein et al., 2005;
Neve et al., 2005).
Each of these two options has advantages and limitations that
should be taken into account. Using a helper-virus will pro-
mote high titer but, with such an approach it is not possible
to completely eliminate helper-virus contaminants. Alternatively,
one can use the co-transfection method, in which the amplicon
and a bacterial artificial chromosome (BAC) harboring the entire
viral genome except for the packaging sequence are introduced
into the producer cell line (Saeki et al., 2001). It is important to
note that sensory neurons are the natural reservoir of latency
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(Kristensson et al., 1971). Nevertheless, gene transfer experiments
have shown that HSV-1-based vectors can establish latency
also in other neurons within the brain (Scarpini et al., 2001;
Berges et al., 2005). However, there is indicative evidence that
latency is not equivalent in all neuron subsets (Labetoulle et al.,
2003), therefore, it is important to elucidate whether long-
term transgene expression is achievable in a variety of neuronal
populations.
ADENO-ASSOCIATED VIRAL VECTORS (AAV)
AAV is a non-enveloped virus harboring an outer protein
capsid and a single-stranded DNA genome, approximately
4.7 kb long. The AAV genome consists of two open reading
frames (ORFs) flanked by ITRs. The first ORF—termed rep—
encodes four proteins that are involved in replication of the
viral genome. The second ORF (cap) encodes three structural
proteins (VP1, VP2, and VP3) (Srivastava et al., 1983). The
ITRs are the minimal required cis-acting elements for viral
genome integration, replication, and packaging into the cap-
sid shell. In recombinant AAV-based vectors, rep, and cap are
replaced with a gene of interest, and are supplied as trans-
acting elements to facilitate transgene packaging inside the cap-
sid. The AAV life cycle includes viral attachment to the cell
surface, viral uptake, genome translocation into the nucleus
and, finally, viral gene expression (Kwon and Schaffer, 2008).
After transduction, the viral genome remains mainly episomal
and, in some cases, integrates randomly into the host genome
(Smith, 2008).
AAV is a naturally defective virus, and upon arrival into
the nucleus, its replication requires functions supplied by a
helper-virus such as an Ad, or it establishes a latent infec-
tion. It is important to clarify that recombinant AAV lacks
both rep and cap genes, therefore, it is replication-deficient
even in the presence of a helper-virus (Richardson and Westphal,
1984; Weindler and Heilbronn, 1991). Since AAV is inherently
replication-defective and lacks any known pathogenicity, it is
an attractive gene transfer vector for use in gene therapy. AAV
has several available serotypes, of which the most studied is
AAV-2, currently used in clinical trials for treatment of numerous
diseases.
AAV-2 has a broad tropism and has been shown to deliver
genes to a wide range of cell types, includingmuscle, brain, retina,
liver, and lung. Nevertheless, a broad tropism can be a draw-
back for targeted gene delivery to specific types of cells, therefore,
efforts have focused on modifying capsid proteins in order to
alter the tropism and enhance the efficiency of transduction
into specific cell types (Kwon and Schaffer, 2008). An additional
consideration that should be taken into account is that gene trans-
fer into the CNS could be compromised by immune responses
against virion components; when AAV is used as a vector pre-
existing circulating antibodies might inhibit gene transfer, thus
limiting its effectiveness.
LENTIVIRAL VECTORS (LVs)
The best-characterized lentiviral vectors (LVs) are derived from
the HIV-1, which is a subclass of retroviruses. However, in con-
trast to most retroviruses, which infect only actively replicating
cells, LVs are capable of infecting both dividing and non-dividing
cells, including fully differentiated neurons (Galimi and Verma,
2002). The natural virus consists of a glycoprotein envelope and
a 9 kb single-stranded-RNA genome. Accordingly, the HIV-1 life
cycle includes a step of reverse-transcription of the RNA genome
into a double-stranded DNA, and a subsequent step of stable
integration into the host-cell genome. This feature is maintained
in HIV-1-based vectors, thereby enabling long-term expression
of the gene of interest.
The HIV-1 genome contains nine ORFs, including the
retroviral genes gag, pol, and env, which encode the structural
proteins polymerase and reverse transcriptase, and envelope
glycoproteins, respectively. Additionally, the LV genome encodes
accessory proteins that function in infection maintenance. These
accessory proteins were removed when the LV was devel-
oped into a gene transfer vector. Moreover, a number of
cis-acting elements are required at various stages of the viral
life cycle; these include the long terminal repeats (LTRs), the
TAT activation region (TAR), splice donor and acceptor sites,
packaging and dimerization signal (), Rev-responsive element
(RRE), and the central and terminal polypurine tracts (PPT)
(Ramezani and Hawley, 2002). Major research efforts have been
dedicated to increasing the vector biosafety: the general strategy
used to produce vector particles that are replication-defective has
been to eliminate all dispensable genes from the HIV-1 genome
and, as far as possible, to separate the cis-acting sequences
from trans-acting factors that are absolutely required for viral
particle production, infection, and integration. This approach
resulted in the establishment of the third-generation self-
inactivating (SIN) LV system (Naldini et al., 1996b; Dull et al.,
1998; Zufferey et al., 1998).
Wild-type LVs have a natural tropism to T lymphocytes, but
this tropism can be altered by pseudotyping. The most widely
used LV pseudotypes are those that incorporate the attachment
glycoprotein of the vesicular stomatitis virus (VSV-G), which
both enables the production of high-titer vector stocks, and con-
fers a broad host range (Jakobsson et al., 2003). Nevertheless,
other pseudotyping options are available, and one can uti-
lize this strategy to obtain cell-specific transduction properties
(Waehler et al., 2007).
Efficient transduction of neurons in vivo was described in the
very first report of a vector system based on HIV-1 (Naldini et al.,
1996a). Since then, hundreds of reports have described the
use of LVs in the CNS, for both therapeutic and experimental
gene transfer purpose. It is important to mention that neu-
rons transduced by LVs are both morphologically and physi-
ologically normal, and remain healthy for many months after
infection. Thus, LVs serve as an efficient tool to study the
CNS, because infection per se has no apparent deleterious effect
(Baekelandt et al., 2002).
ADVERSE EFFECTS OF LV-MEDIATED MANIPULATION
Several potential adverse effects of LV injection should be taken
into account when using LVs as a vector (Pauwels et al., 2009).
(1) Replication-competent lentiviruses (RCL) could be produced
during the generation and propagation of LV production; gener-
ation of RCLs might arise through homologous recombination
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between overlapping sequences, and to prevent this a four-
plasmid vector system is used in the third-generation LV, so
that RCL may occur only after a number of recombination
events (Dull et al., 1998). Although RCL events have not been
detected so far, because of the SIN vector design, the possibil-
ity of such events should still be taken into account. (2) Because
the LV produced DNA is inserted into the host-cell genome, the
insertion might be associated with increased risk of insertional
mutagenesis and transactivation of genome sequences. For exam-
ple, high incidence of oncogenesis was detected following gene
transfer with EIAV (equine infectious anaemia virus)-derived
LVs in neonatal mice, and it was thought to be associated with
insertional mutagenesis or transactivation (Themis et al., 2005).
Studies have shown that LVs preferentially integrate into tran-
scriptionally active genes, therefore, LV integration into such
genes might be considered to pose a risk of tumorogenesis
because of, for instance, the loss of normal tumor-suppressor
gene functions. Furthermore, transactivation of neighbouring
genome sequences is a risk, in the light of studies indicat-
ing that the LV enhancer/promoter elements have a role in
cell transformation.
In order to address these major biosafety concerns, research
is being conducted to develop integration-deficient lentiviral
vectors (IDLVs). In contrast to integrating lentivectors, IDLVs
remain as episomal DNA, and pose a much smaller risk of
causing insertional mutagenesis and a lower risk of generat-
ing RCL. Currently, IDLV systems can mediate transient gene
expression in proliferating cells, and stable expression in non-
dividing cells in vitro and in vivo (Wanisch and Yanez-Munoz,
2009). In the CNS, stereotactic injections of IDLVs into mouse
or rat brain established efficient Green Fluorescent Protein
(GFP) expression which was stable for up to one month
(Fabes et al., 2006; Markowitz et al., 2007); in all cases no dif-
ferences were observed between integrating and non-integrating
LVs, in their proficiency of titer matching in quiescent tissues
(Markowitz et al., 2007).
TEMPORAL AND SPATIAL CONTROL OF
LENTIVIRAL-MEDIATED GENETIC MANIPULATIONS
A major challenge in neuroscience is to define the roles of spe-
cific molecules in brain function, within neuronal circuits and
in synaptic plasticity processes. To advance this type of research,
genetic modifications need to induce refined manipulations, i.e.,
changes specific to a time and/or place such as a particular brain
area or neuron population. Improved control of gene manipu-
lation has been accomplished by utilization of genetically engi-
neered mice harboring regulatory elements in addition to the
gene of interest.
Two main systems were applied to introduce control-
lable genetic modifications: the Cre-LoxP system and the
tetracycline-dependent transcription system. Cre recombinase is
an enzyme isolated from bacteriophage P1, which specifically
recombines two 34-bp loxP recognition sites. This charac-
teristic of Cre recombinase is utilized to target recombina-
tion events in the mouse genome, endogenously devoid of
loxP sites (Hoess et al., 1982, 1986; Sauer and Henderson, 1988).
The Cre-LoxP approach was effectively applied in the field
of neuroscience initially in creating mice lacking functional
N-methyl D-aspartate (NMDA) receptors, specifically in the
CA1 region of the hippocampus (Tsien et al., 1996a,b). This
cell-type-specific manipulation required crossing of two dis-
tinct mouse lines. In one of these mouse lines, established by
standard transgenic techniques, Cre recombinase is expressed
under regulation of the brain-region-specific αCaMKII pro-
moter; the second was generated by homologous recombina-
tion in Embryonic Stem (ES) cells, in which loxP sites were
inserted into intronic and downstream sequences surround-
ing the NMDA receptor 1 gene. Cross-breeding of these two
mouse lines resulted in deletion of the NMDAR1 gene only
in Cre-recombinase-expressing neurons, thus providing a brain-
region-specific genetic manipulation. Temporal fine tuning of the
Cre-LoxP system was further, achieved by generation of ligand-
dependent Cre recombinase (CreERT2), which is active only
in the presence of specific ligands. CreERT2 is a fusion pro-
tein in which Cre enzyme has been fused to a mutant estrogen
receptor fragment. This fusion protein is not activated by endoge-
nous estrogen, but is sensitive to a synthetic ligand, tamoxifen.
CreERT2 is localized in the cell cytoplasm and upon binding
to tamoxifen enters the nucleus to mediate recombination of
loxP sites (Metzger and Chambon, 2001). Therefore, in CreERT2
expressing cells, temporal control is accomplished by tamoxifem
administration.
The tetracycline-dependent Tet/tetO system was developed
by Hermann Bujard and colleagues, and is based on the
tetracycline resistance of bacteria (Gossen and Bujard, 1992;
Furth et al., 1994). The basic principal involves introduction of
an exogenous molecule with unknownmammalian targets, which
is able to regulate transcription in an inducible and reversible
manner. The Tet/tetO system consists of two elements: a tran-
scription repressor (TetR), and a DNA motif specific for TetR
binding and named tetO sequence. The tTA is a fusion protein
composed of the TetR repressor and the VP16 transcription acti-
vation domain from the HSV. The tTA binds to the tetO element
and activates the transcription of the nearby gene. Binding of
tTA to the antibiotic tetracycline derivative, doxycycline, lowers its
affinity to tetO thereby preventing transactivation of target genes
(Tet-off). In a modified version of this system a four-amino-acid
change in the tetR DNA binding domain alters the tTA binding
properties, thereby, creating the rtTA protein that, in contrast
to the tTA, can recognize only the tetO sequences and activate
transgene expression in the presence of the tetracycline analog
doxycycline (Tet-on). Thus, by controlling the doxycycline supply
to the genetically engineered mouse we can turn the expression of
a gene downstream of the tetO sequence on or off, depending on
the Tet system used.
Mouse models harboring the regulatory systems described
above can serve as a valuable tool for elucidating brain func-
tion in health and under pathological conditions. However, these
techniques suffer from several limitations. First, some promot-
ers may facilitate a cell-type-specific expression in one mouse
strain, but will fail to do so when transferred to a different
strain (Gupta et al., 2001; Everett et al., 2004). Second, several
examples indicated that different mouse strains behaved differ-
ently, a phenomenon that can complicate behavioral analysis
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of the impact of the genetic manipulation (Miller et al., 2010;
Lederle et al., 2011). Moreover, in transgenic approaches, the
manipulation is performed at the germline level, which limits
development of potential therapeutic agents. Stereotactic delivery
of viral vectors to relevant brain regions provides an alternative
to traditional mouse genetics and enables relatively high spatio-
temporal control over the genetic manipulation, and a short
time from experimental design to data collection and analysis.
Currently, lenti- and adeno-associated viral vectors are regarded
as best-choice tools for gene manipulation in the CNS. The per-
formance of LVs is superior to that of AAVs with regard to
packaging capacity, stability of transgene expression, and absence
of an inflammatory response.
In order to achieve temporal and spatial control of
LV-mediated gene manipulation, two main strategies are avail-
able. The first involves combination of the LV gene trans-
fer approach and a Cre mouse model, in which the Cre
recombinase is expressed under the regulation of a cell-type-
specific promoter, and the LV contains a trangene that is reg-
ulated via loxP sites e.g., by using a loxP-flanked stop cassette
between the transgene and its promoter. Another possibil-
ity is to apply a vector that carries a doubly floxed inverted
gene. Upon transduction into Cre recombinase-expressing cells,
the gene will be irreversibly inverted and enable cell-specific
gene expression (Cardin et al., 2010; Zhang et al., 2010). The
identification of cell-type-specific promoters is crucial for the
success of cell-specific gene targeting. Initially, the neuronal
population as a whole was targeted by using expression of
neuron-specific enolase (NSE) minimal promoter-derived Cre.
Since then a significant number of brain-region and cell-type-
specific, Cre-dependent regulated systems have been established
in mice and are expanding rapidly (Gavériaux-Ruff and Kieffer,
2007). Websites of Nagy (www.mshri.on.ca/nagy/) and Jackson
(www.jax.org/) laboratories are recommended for finding avail-
able Cre mice. In addition, transgenic BAC-Cre recombi-
nase driver lines can be found in the GENSAT database
(www.gensat.org/cre.jsp).
Similarly, one could employ the Tet system (Gascon et al.,
2008; Hioki et al., 2009; Konopka et al., 2009): a single LV vec-
tor can contain both the rtTA transactivator that is regulated by a
cell-type-specific promoter, and a transgene expression cassette
that is regulated by a promoter containing tetO sequences. In
such a case the transgene expression is regulated by the presence
of Dox in the brain. Thus, temporal control is achieved by Dox
administration or removal, and spatial regulation is induced by
cell-type-specific promoters.
A different approach for targeted LV-mediated gene trans-
fer is to use envelope proteins that bind to specific receptors
found only on the desired cell type; a process known as pseu-
dotyping. As mentioned above, LV vectors are most frequently
pseudotyped with the VSV-G glycoprotein, which has broad
tropistic properties. Moreover, VSV-G-pseudotyped LV particles
are resistant to freeze-thaw cycles as well as to ultracentrifuga-
tion during production, which aremajor aspects for gene-delivery
vectors. Nevertheless, an optimal in vivo gene manipulation
in the adult brain should facilitate cell-type-specific targeting.
Selective tropism can be achieved by using the natural tropism
of glycoproteins from other membrane-enveloped viruses. For
instance, Mazarakis and colleagues demonstrated that pseu-
dotyping of LVs with rabies-G glycoprotein enhanced gene
transfer into neurons by facilitating retrograde axonal trans-
port and transduction of neurons at distally connected sites
within the nervous system (Wong et al., 2004). Another option
is to apply ligand-receptor bridge proteins. Recently pub-
lished findings demonstrated a successful application of bridge
protein targeting of a LV to selected cells within the brain
in vivo: cortical ErbB4-expressing neurons were targeted in
vivo by using an EnvB-pseudotyped LV and the TVB–NRG1
bridge protein (Choi et al., 2010). Alternatively, single-chain anti-
bodies that recognize cell-surface antigens can also be uti-
lized to direct LV particles into specific neuronal populations
(Anliker et al., 2010).
Direct LV mediated gene delivery into the adult brain rep-
resents a powerful tool in neuroscience research. Temporal and
spatial control of LV-mediated genetic modifications can be
facilitated by the strategies described above, because of the rel-
atively high packaging capacity. It is worth mentioning that
different gene expression regulation systems in LVs can be com-
bined to induce fine tuning of time- and place-directed genetic
modifications.
LV-MEDIATED GENE MANIPULATION IN DIFFERENT
TEMPORAL PHASES OF LEARNING/MEMORY PROCESSES
Research into the molecular and cellular mechanisms under-
lying learning, memory, and synaptic plasticity processes is
increasingly using various genetic tools, including viral vectors.
One can divide the research on synaptic plasticity and mem-
ory into the following fields according to area of study and
research tools. (1) Study of neuronal synaptic or intrinsic func-
tions and properties by using electrophysiology and/or imaging
techniques. (2) Elucidating neuronal functions and/or neuronal
circuits within a given brain area by using imaging and opto-
genetic tools, and (3) Gaining understanding of the molecu-
lar and cellular mechanisms underlying learning and memory
processes, with a specific aim of going beyond mere correla-
tions, to prove the causality of molecular processes underlying
learning.
Within the scope of the present review we focus mainly on
studies that used viral genemanipulation in learning andmemory
processes—manipulation that aimed to dissect out the various
phases of memory formation and storage: acquisition, consoli-
dation, and maintenance. These studies pioneered the field and
aimed to show causality between molecular and cellular events
in specific brain regions, on the one hand, and specific phases
of memory formation, on the other hand. We, therefore, put the
spotlight specifically on use of the LV technique to investigate
molecular mechanisms of memory formation in the gustatory
cortex (GC), in taste memory formation (Elkobi et al., 2008;
Shema et al., 2011).
One such type of learning paradigm comprises cortically
dependent taste-learning paradigms in rodents. Taste memories,
like any other sensory memory, can be formed and maintained
without any associative external input, i.e., incidental learn-
ing (Merhav and Rosenblum, 2008), or can be associated with
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malaise to induce long-lasting negative memory, i.e., condi-
tioned taste aversion (CTA) (Garcia et al., 1955). The functional
integrity of the GC, which resides within the insular cortex (IC),
is necessary both for creation of new positive or negative taste
memories and also for maintaining these memories over time
(Rosenblum, 2009). Rodents rely heavily on their chemical senses,
which makes novel taste learning a natural and robust behavior
to study at the anatomical, physiological, and molecular levels
(Rosenblum et al., 1997; Jones et al., 1999; Berman et al., 2000;
Merhav et al., 2006; Yefet et al., 2006).
At the biochemical level, novel taste learning is associated
with changes in the phosphorylation state of several proteins,
including extra-cellular regulated kinase (ERK1/2), Elk-1, and
the 2B subunit of the NMDA receptor (Rosenblum et al., 1997;
Berman et al., 2000; Barki-Harrington et al., 2009), expression
levels of C/EBPβ (Yefet et al., 2006), and modulation of the pro-
tein synthesis machinery (Banko et al., 2006; Belelovsky et al.,
2005, 2007, 2009). Inhibition of protein synthesis in the IC
during novel taste learning disrupted long- but not short-
term taste memory (Rosenblum et al., 1993; Houpt and Berlin,
1999; Merhav and Rosenblum, 2008). A proteomic study
revealed induced expression of PSD-95 (post-synaptic pro-
tein 95/DLG1) in the GC, 3 h after novel taste learning
(Elkobi et al., 2008). PSD-95 belongs to a family of synaptic scaf-
fold proteins, PDZ-containing proteins, whose expression levels
affect both depression, and potentiation of synaptic plasticity
(Ehrlich and Malinow, 2004; Ehrlich et al., 2007).
In order to test the hypothesis that PSD-95 induction is
necessary for memory formation, LVs containing RNAi to silence
PSD-95 and EGFP as a fluorescent reporter were injected into
the rat GC, before or after CTA training. Scrambled shRNA
sequence or empty vectors were used as controls. In RNAi-
injected rats there was no correlative induction of PSD-95 in
the GC 3 h after taste learning, and CTA memory was dimin-
ished. However, the same manipulation of PSD-95 levels by
using LVs expressing RNAi to silence PSD-95 in the GC after
CTA training did not have any effect on memory retrieval or
maintenance (Elkobi et al., 2008). These results indicated that
transient increase in PSD-95 expression in the relevant cortical
area is necessary for memory consolidation, but not for mainte-
nance processes (Elkobi et al., 2008). The roles of other synaptic
scaffold proteins such as PSD-93, SAP97, or SAP102 are yet
to be studied.
In another set of experiments, researchers who were interested
specifically in the processes underlying taste memory mainte-
nance in the GC examined the role of PKMζ, which is an active
form of PKM that peptide pharmacology has revealed to be
relevant in Long-term Potentiation (LTP) and memory main-
tenance (Sacktor, 2008). By using an interfering peptide (ZIP
sequence), it was shown that microinjection of PKMζ inhibitor
into the GC long after CTA training diminished CTA memory
but did not affect the ability to learn a new CTA association
with a different taste (Shema et al., 2007). In a recent paper, the
same authors used LVs expressing either RNAi to silence PKMζ
or over-expression of PKMζ in the GC, weeks after CTA train-
ing. Indeed, by using LVs, the authors were able to manipulate
PKMζ expression levels specifically in the GC, long after
acquisition took place: reducing the expression of PKMζ attenu-
ated CTAmemory, whereas over-expression of PKMζ enhanced it
(Shema et al., 2011).
Taken together, the above results demonstrate the potential
for manipulating gene expression in the rodent brain by using
LV vectors. However, one should take into account several ques-
tions, both technical and fundamental, that arise in this type of
research. (1) Circuit questions, for example, what is the iden-
tity of cells responsible for such a strong behavioral phenotype?
(2) Molecular questions regarding the integration site of the LV
in these cells, and whether it plays a role in the phenotype. (3)
Questions regarding the site of interference: does the phenotype
relate directly to the target protein, or to a sequence of molec-
ular events that were not addressed in the above studies? We
believe that viral vector tools, together with well controlled phys-
iological and behavioral analysis, will enable researchers to put
the correlative molecular information into the context of a spe-
cific neuronal circuit, as was shown recently in the amygdala
(Ciocchi et al., 2010).
CONCLUDING REMARKS
The field of viral-vector-mediated gene manipulation in the
adult brain has achieved impressive progress during the last
decade. In particular, LVs have now become a recognized exper-
imental tool in neuroscience research; they offer interesting
approaches for controlled, localized genetic manipulation in
neurons, particularly in manipulating gene-targeted or trans-
genic mice. One major aspect that should be taken into account
is the limited spread of LVs in the extracellular space (ECS)
of the vertebrate brain, a feature that facilitates transduction
of neurons located close to the injection site, but that makes
these vectors inefficient in manipulating large populations of
neurons. On the other hand, injection-based delivery provides
modification that is highly specific in both time and loca-
tion, which makes targeting of small neuronal populations
with distinct cellular functions relatively easy. In addition, the
fact that only a small number of neurons are transduced
means that gene functions can be altered in a way that would
not generate a lethal phenotype, or activate compensation
mechanisms.
Vector systems may provide controllable therapy of the dis-
eased brain. Knowledge regarding LV-mediated gene modifica-
tion and its consequences is expanding continuously, and the
technology is developing rapidly, therefore, this system is more
attractive than other viral vectors. In viral-mediated human gene
therapy a major cause for concern is possible induction of the
host immune response; however, lack of established immunity to
LVs in the majority of subjects represents an advantage over other
vector systems, such as AAV and Ad.
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